Market Overview:
The global human rabies immune globulin (HRIG) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The HRIG market is segmented on the basis of type, application and region. On the basis of type, the HRIG market is segmented into 200IU and 500IU. The 200IU segment is expected to account for a larger share in terms of revenue in 2018, owing to its lower price point as compared to 500IU segments. However, the 500 IU segments are projected to grow at a higher CAGR during the forecast period due to increasing demand for high potency HRIG products. On the basis of application, category II exposure accounted for majority share in terms revenue in 2017 and it is projected that this trend would continue over forecast period as well .
 Industry Outlook.svg)
Product Definition:
Human Rabies Immune Globulin (HRIG) is a purified antibody preparation made from the plasma of human donors hyperimmunized with rabies vaccine. It is used to provide temporary immunity to people who have been exposed to rabies virus.
200IU:
200IU is a Human Rabies Immune Globulin (HRIG) used for the treatment of human rabies. It is manufactured by extracting plasma from the blood of immunized donors and purification through an anticoagulant solution. The product has been approved by the U.
500IU:
500IU is Human Rabies Immune Globulin. It is used in the treatment of human rabies infection. HRIG contains antibodies that fight against the virus causing rabies and neutralize its toxic effects. The product also helps to control various adverse reactions caused by the disease such as hydrophobia (fear of water) and aerophobia (difficulty in respiration).
Application Insights:
On the basis of application, the global market has been segmented into category II and III exposure. Category II exposure held a larger share in 2017 as a result of higher incidence of human rabies cases due to unvaccinated animals and travelers from countries where rabies is prevalent. In addition, factors such as lack of awareness about vaccination among animal owners and improper disposal of carcasses by travelers are also expected to drive demand for HRIG for category II exposure during the forecast period.
The growing number of healthcare professionals traveling abroad for work along with an increase in international medical tourism is also expected to contribute toward growth over the forecast period. An increasing number or deaths caused by bat bites across several regions coupled with rising incidencesof lyssavirus infection are further anticipated to spur demand globally over the coming years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a well-developed healthcare infrastructure and favorable reimbursement policies are some of the major factors contributing to its growth. In addition, increasing number of animalbite cases is also expected to drive regional demand for rabies immunoglobulin during the forecast period. According to statistics published by CDC, around 60,000 people are bitten each year by dogs in U.S., which is approximately three times higher than that reported from India (21,000).
Asia Pacific region accounted for over 23% share in 2017 owing to growing awareness about vaccination programs and rising incidence rates of animal bites across countries such as India and China. Furthermore, government initiatives coupled with high R&D investment by leading manufacturers will further propel industry growth over the next eight years.
Growth Factors:
- Increasing incidence of rabies across the globe
- Growing awareness about the benefits of HRIG therapy
- Rising demand for prophylactic and post-exposure treatments for rabies
- Technological advancements in HRIG manufacturing process
- Growing number of collaborations and partnerships between pharmaceutical companies
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Rabies Immune Globulin (HRIG) Market Research Report
By Type
200IU, 500IU
By Application
Category II Exposure, Category III Exposure
By Companies
CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Human Rabies Immune Globulin (HRIG) Market Report Segments:
The global Human Rabies Immune Globulin (HRIG) market is segmented on the basis of:
Types
200IU, 500IU
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Category II Exposure, Category III Exposure
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Behring
- Grifols
- Sanofi
- Sichuan Yuanda Shuyang
- CNBG
- Kamada
- CBPO
- Shuanglin Bio
- Weiguang Bio
- Shanghai RAAS
- Bharat Serum
- VINS
 Market Overview.svg)
Highlights of The Human Rabies Immune Globulin (HRIG) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 200IU
- 500IU
- By Application:
- Category II Exposure
- Category III Exposure
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Rabies Immune Globulin (HRIG) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HRIG is a human vaccine used to prevent rabies. HRIG is made from human plasma and contains antibodies that help protect against rabies.
Some of the major companies in the human rabies immune globulin (hrig) market are CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS.
The human rabies immune globulin (hrig) market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Rabies Immune Globulin (HRIG) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Rabies Immune Globulin (HRIG) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Rabies Immune Globulin (HRIG) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Rabies Immune Globulin (HRIG) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Rabies Immune Globulin (HRIG) Market Size & Forecast, 2018-2028
4.5.1 Human Rabies Immune Globulin (HRIG) Market Size and Y-o-Y Growth
4.5.2 Human Rabies Immune Globulin (HRIG) Market Absolute $ Opportunity
Chapter 5 Global Human Rabies Immune Globulin (HRIG) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Human Rabies Immune Globulin (HRIG) Market Size Forecast by Type
5.2.1 200IU
5.2.2 500IU
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Human Rabies Immune Globulin (HRIG) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Human Rabies Immune Globulin (HRIG) Market Size Forecast by Applications
6.2.1 Category II Exposure
6.2.2 Category III Exposure
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Rabies Immune Globulin (HRIG) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Rabies Immune Globulin (HRIG) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Human Rabies Immune Globulin (HRIG) Analysis and Forecast
9.1 Introduction
9.2 North America Human Rabies Immune Globulin (HRIG) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Human Rabies Immune Globulin (HRIG) Market Size Forecast by Type
9.6.1 200IU
9.6.2 500IU
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Human Rabies Immune Globulin (HRIG) Market Size Forecast by Applications
9.10.1 Category II Exposure
9.10.2 Category III Exposure
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Human Rabies Immune Globulin (HRIG) Analysis and Forecast
10.1 Introduction
10.2 Europe Human Rabies Immune Globulin (HRIG) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Human Rabies Immune Globulin (HRIG) Market Size Forecast by Type
10.6.1 200IU
10.6.2 500IU
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Human Rabies Immune Globulin (HRIG) Market Size Forecast by Applications
10.10.1 Category II Exposure
10.10.2 Category III Exposure
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Human Rabies Immune Globulin (HRIG) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Human Rabies Immune Globulin (HRIG) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Human Rabies Immune Globulin (HRIG) Market Size Forecast by Type
11.6.1 200IU
11.6.2 500IU
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Human Rabies Immune Globulin (HRIG) Market Size Forecast by Applications
11.10.1 Category II Exposure
11.10.2 Category III Exposure
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Human Rabies Immune Globulin (HRIG) Analysis and Forecast
12.1 Introduction
12.2 Latin America Human Rabies Immune Globulin (HRIG) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Human Rabies Immune Globulin (HRIG) Market Size Forecast by Type
12.6.1 200IU
12.6.2 500IU
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Human Rabies Immune Globulin (HRIG) Market Size Forecast by Applications
12.10.1 Category II Exposure
12.10.2 Category III Exposure
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Human Rabies Immune Globulin (HRIG) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Human Rabies Immune Globulin (HRIG) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Human Rabies Immune Globulin (HRIG) Market Size Forecast by Type
13.6.1 200IU
13.6.2 500IU
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Human Rabies Immune Globulin (HRIG) Market Size Forecast by Applications
13.10.1 Category II Exposure
13.10.2 Category III Exposure
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Rabies Immune Globulin (HRIG) Market: Competitive Dashboard
14.2 Global Human Rabies Immune Globulin (HRIG) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL Behring
14.3.2 Grifols
14.3.3 Sanofi
14.3.4 Sichuan Yuanda Shuyang
14.3.5 CNBG
14.3.6 Kamada
14.3.7 CBPO
14.3.8 Shuanglin Bio
14.3.9 Weiguang Bio
14.3.10 Shanghai RAAS
14.3.11 Bharat Serum
14.3.12 VINS
